Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash.
Open Access
- 1 February 1986
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 45 (2) , 139-140
- https://doi.org/10.1136/ard.45.2.139
Abstract
Sulphasalazine has been shown to be useful in the management of rheumatoid arthritis. However, its use may be complicated by a skin rash. Eight patients with a rash have undergone desensitisation, the aim of which was to achieve a daily dose of 2 g sulphasalazine. This was successful in five patients, partially successful in two, and failed in one patient. Desensitisation to sulphasalazine is a simple outpatient procedure, which subsequently allows the majority of patients developing a skin rash to continue treatment.This publication has 4 references indexed in Scilit:
- Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.Annals of the Rheumatic Diseases, 1985
- Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.BMJ, 1983
- Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.BMJ, 1983
- Sulphasalazine desensitisation.BMJ, 1981